Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

com" target="_new">http://www.pharmacyclics.com. The archived version of the webcast will be available on the company's website for one month.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and immune diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about projected operating expenses, plans for initiating Phase 1 trials for PCI-27483 and PCI-32765, plans to conduct a pivotal Phase 3 trial for motexafin gadolinium, and other future plans and timelines for our preclinical studies and clinical trials, progress of and reports of results from preclinical studies and clinical trials, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the tim
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... USA (PRWEB) September 20, 2014 Entries ... 2015 Prism Awards for Photonics Innovation . The ... the multi-billion dollar optics and photonics industry, and is ... and photonics , and Photonics Media . , ... the versatility of photonics, said SPIE CEO Eugene Arthurs. ...
(Date:9/19/2014)... YORK, September 18, 2014 Scientists at NYU Langone ... dramatically the efficiency of the process for turning adult ... well-known compounds, including vitamin C. Using the new technique ... cells obtained from adult skin cells by more than ... technique is efficient and reliable, and thus should generally ...
(Date:9/19/2014)... FRANCISCO , Sept. 19, 2014  Nektar ... results from preclinical studies characterizing the analgesic profiles ... peripherally-acting kappa opioid receptor agonist molecules. The preclinical ... polymer medicinal chemistry platform. The analgesic ... in the medical literature. 1,2 Kappa opioid ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
Breaking Biology Technology:Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... Broadway Hotel in New York on Thursday, ... ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... Executive Officer, will present at,the NewsMakers in the Biotech Industry investment ...
... Belgium, August 24 ThromboGenics NV (Euronext,Brussels: THR), ... a business update and its financial results for ... this period, ThromboGenics has raised,additional funds to invest ... good progress with its clinical programs. Highlights ...
... Stem cell company,Neuralstem, Inc. (OTC Bulletin Board: NRLS) ... on the American Stock Exchange(R) (Amex(R)),under the symbol CUR. ... August 27, 2007. "Moving to the Amex is ... of the continuous and significant progress the company has ...
Cached Biology Technology:Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 4ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 5ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 6ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 7ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 8ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 9ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 10ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 11Neuralstem Shares Accepted for Trading on Amex(R) 2
(Date:9/21/2014)... T cells may have the ability to trigger an ... led by King,s College London. Although their immune system ... still be able to mount a strong immune defense, ... Medicine . , Our immune system is made up ... which play an important role in the frontline defense ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... you are a species which over thousands of years has ... to a substance that makes the cold dangerous for you. ... Enchytraeus albidus , and the cold provoking substance, called nonylphenol, ... , Nonylphenol is suspected of being a endocrine disruptor, but ... inhibits the worm,s ability to protect the cells in its ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... of Preventive Medicine (ACPM) has launched a web ... medicine the practice of changing health behaviors to ... The document summarizes scientific evidence supporting lifestyle interventions. ... such as definitions, reimbursement trends, related practice patterns, ...
... advent of the Human Genome Project an explosion of data ... demand to fine-tune genomic codes, which list the "ingredients for ... A Rutgers UniversityCamden biochemist is addressing this ... "background checks" on all known enzyme functions. Thanks to ...
... increases in obesity and associated diseases -- and fiery debates ... team has identified a new genetic mechanism that controls the ... to new treatments for obesity and type 2 diabetes, and ... people and dramatically cut health care costs. A research ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2Rutgers-Camden developing enzyme function database 2UCF discovery could open door to obesity, diabetes treatments 2
... The ProteoSpin Detergent Clean-up Micro Kit provides ... removal of SDS, Triton X-100 and other detergents ... spin-column chromatography using Norgens patented protein resin as ... processing 2 50 g of either acidic or ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... hematopoietic stem cells called monocytes. Osteoclasts resorb ... and lowering the surrounding pH to an ... mineral is then solubilized and the collagen ... primarily by Macrophage Colony-Stimulating Factor (M-CSF) and ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: